Xeris Biopharma Holdings (XERS) Return on Equity (2021 - 2025)
Xeris Biopharma Holdings (XERS) has disclosed Return on Equity for 5 consecutive years, with 0.09% as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Return on Equity fell 181.0% year-over-year to 0.09%, compared with a TTM value of 0.09% through Dec 2025, down 181.0%, and an annual FY2025 reading of 0.07%, down 308.0% over the prior year.
- Return on Equity was 0.09% for Q4 2025 at Xeris Biopharma Holdings, down from 1.55% in the prior quarter.
- Across five years, Return on Equity topped out at 42.68% in Q4 2023 and bottomed at 10.76% in Q3 2021.
- Average Return on Equity over 5 years is 1.49%, with a median of 1.44% recorded in 2022.
- The sharpest move saw Return on Equity surged 4457bps in 2023, then tumbled -4079bps in 2024.
- Year by year, Return on Equity stood at 2.65% in 2021, then rose by 29bps to 1.89% in 2022, then soared by 2360bps to 42.68% in 2023, then plummeted by -96bps to 1.89% in 2024, then crashed by -95bps to 0.09% in 2025.
- Business Quant data shows Return on Equity for XERS at 0.09% in Q4 2025, 1.55% in Q3 2025, and 1.18% in Q2 2025.